View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 28, 2018updated 20 Jul 2022 9:01am

Baxter secures FDA clearance for Altapore Bioactive Bone Graft

Baxter International has obtained the US Food and Drug Administration (FDA) clearance for the use of the new Altapore Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion.

Baxter International has obtained the US Food and Drug Administration (FDA) clearance for the use of the new Altapore Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion.

The next-generation osteoconductive bone graft substitute already has clearance for application in orthopaedic surgeries of the extremities and pelvis.

The Altapore Bioactive Bone Graft has been developed to improve bone growth with optimised porosity to promote early vascularisation, which provides oxygen, nutrients and growth factors needed for bone formation.

“When used as an autograft extender in a pre-clinical posterolateral spinal fusion model, Altapore Bioactive Bone Graft demonstrated similar fusion rates to existing standard of care, iliac crest autograft, in spine surgical techniques.”

The graft’s porosity also enhances cellular activity by offering more surface area for cells to travel along its surface. This further promotes the development of new bone.

Altapore is said to feature precise handling characteristics that enable putty moulding into various shapes to address different surgical needs.

Baxter International Advanced Surgery business president Wil Boren said: “Providing surgeons with versatile tools like Altapore is critical to our commitment to partner with clinicians to advance healing in the operating room.

“With this clearance, more surgeons will have access to this innovative bone graft substitute as we look to improve outcomes across our entire portfolio of surgical products.”

When used as an autograft extender in a pre-clinical posterolateral spinal fusion model, Altapore Bioactive Bone Graft demonstrated similar fusion rates to existing standard of care, iliac crest autograft, in spine surgical techniques.

In addition to Altapore, Baxter’s osteobiologic surgical products portfolio includes Actifuse Shape, Actifuse MIS, Actifuse ABX and Actifuse Flow.

The company received the FDA clearance for Actifuse Flow earlier this month. This bone graft substitute is a pre-packaged delivery syringe used to accelerate bone growth.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network